Skip to main content

Advertisement

Table 1 Comparison between AD patients (A+T+N+ classification) who were included and not included in the analyses due to missing data

From: CSF level of β-amyloid peptide predicts mortality in Alzheimer’s disease

Characteristics AD patients with A+T+N+ profile
Included Not included  
(N = 321) (N = 61) P value
Age, year, mean (SD) 71.0 (8.5) 71.3 (8.1) 0.68
Women, n (%) 200 (62.3) 37 (59.7) 0.70
MMSE, mean (SD) 20.3 (5.8) 20.3 (6.7) 0.85
Level of education, n (%)a
 Low 106 (35.8) 15 (31.9)  
 Intermediate 110 (36.8) 11 (23.4)  
 High 81 (27.4) 21 (44.7) 0.04
CSF biomarkers, pg/mL, mean (SD)
 Aβ42 483.8 (134.8) 471.8 (133.7) 0.52
 Aβ40b 13,345 (5447) 13,323 (4812) 0.92
 Ratio Aβ42/40b 0.047 (0.022) 0.044 (0.017) 0.57
 Tau 684.9 (276.9) 671.8 (285.9) 0.72
 p-Tau 181 102.6 (39.0) 100.9 (39.5) 0.73
  1. A+T+N+ profile: Abnormal values for three CSF biomarkers (Aβ42, total tau, phosphorylated tau (p-tau 181))
  2. AD Alzheimer’s disease, SD standard deviation
  3. aLow: primary school or less, intermediate: secondary to high school, high: baccalaureate or university degree
  4. bCSF Aβ40 was available for 255 patients